Skip to main content

Table 1 Clinical baseline characteristics of 667 patients hospitalized with symptomatic heart failure according to HFE genotype

From: Hereditary Hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis

HFE variant C282Y H63D S65C Any variation
Status Carrier non-carrier Carrier non-carrier Carrier non-carrier Carrier Non-carrier
n total 73 594 144 523 26 641 231 436
Clinical data         
Age (years) 72.0 (43.6-86.8) 71.1 (49.5-85.9) 71.3 (46.5-87.8) 71.1 (49.5-85.3) 72.6 (46.0-80.6) 71.1 (48.4-86.0) 71.5 (46.0-87.1) 71.0 (50.0-85.9)
male 55 (75) 430 (72) 106 (74) 379 (72) 18 (69) 467 (73) 170 (74) 315 (72)
BMI (kg/m2) 26.4 (20.3-35.1) 26.0 (18.8-35.3) 26.4 (18.7-34.4) 25.9 (19.2-35.3) 26.0 (16.7-44.7) 26.0 (19.1-35.1) 26.3 (19.2-35.1) 25.8 (19.1-35.3)
Current smoker (%) 21 (29) 191 (33) 41 (29) 171 (33) 11 (44) 201 (32) 69 (30) 143 (33)
NYHA classes (%)         
NYHA class I 1 (1) 21 (3) 7 (5) 10 (2) 0 17 (3) 8 (3) 9 (2)
NYHA class II 12 (16) 181 (28) 42 (29) 122 (23) 6 (23) 158 (25) 58 (25) 106 (24)
NYHA class III 47 (64) 360 (56) 76 (53) 315 (61) 15 (58) 376 (59) 132 (57) 259 (60)
NYHA class IV 13 (18) 80 (12) 19 (13) 73 (14) 5 (19) 87 (14) 33 (14) 59 (14)
Medical history         
CHF (%) 62 (86) 502 (85) 115 (80) 449 (86) 23 (86) 541 (85) 189 (83) 375 (86)
IHD (%) 30 (41)* 317 (53) 65 (45) 282 (54) 14 (54) 333 (52) 104 (45)¤ 243 (56)
Former AMI (%) 23 (32) 217 (37) 51 (35) 189 (36) 9 (36) 231 (36) 78 (34) 162 (37)
Hypertension (%) 24 (33) 139 (23) 36 (25) 127 (24) 9 (35) 154 (24) 66 (29) 97 (22)
COPD (%) 14 (19) 127 (21) 31 (22) 110 (21) 8 (31) 133 (21) 52 (23) 89 (20)
Diabetes diagnosis (%) 13 (18) 102 (17) 25 (17) 90 (17) 7 (27) 108 (17) 42 (18) 73 (17)
Hyperlipidaemia (%) 22 (32) 217 (37) 50 (35) 189 (37) 9 (36) 230 (37) 76 (34) 163 (38)
Stroke/TCI (%) 14 (19) 70 (12) 16 (11) 68 (13) 6 (23) 78 (12) 34 (15) 50 (11)
Medication at discharge         
ACE-I (%) 52 (72) 474 (80) 115 (80) 411 (79) 20 (77) 506 (79) 178 (77) 348 (80)
AT-II blockers (%) 7 (10) 53 (9) 13 (9) 47 (9) 4 (15) 56 (9) 24 (10) 36 (8)
β-Blokage (%) 43 (60) 298 (50) 70 (49) 271 (52) 14 (54) 327 (51) 121 (53) 220 (51)
Diuretics (%) 71 (99) 578 (98) 142 (99) 507 (98) 25 (96) 624 (98) 226 (98) 423 (98)
Paraclinical data         
WMI 1.0 (0.4-1.2) 0.9 (0.5-1.2) 0.9 (0.5-1.2) 0.9 (0.4-1.2) 0.9 (0.4-1.2) 0.9 (0.5-1.2) 0.9 (0.4-1.2) 0.9 (0.5-1.2)
Serum Ferritin (ng/ml) 121 (31-582) 123 (35-430) 129 (29-430) 122 (36-443) 159 (42-260) 121 (35-461) 127 (29-417) 121 (37-466)
Hemoglobin (mmol/l) 8.8 (7.1-10.8) 8.6 (6.7-10.4) 8.7 (7.0-10.4)† 8.6 (6.7-10.4) 8.4 (6.9-9.6) 8.6 (6.8-10.4) 8.7 (7.0-10.4)¶ 8.5 (6.6-10.4)
Serum creatinin (μmol/l) 99 (68-259) 106 (68-203) 108 (70-201) 104 (67-208) 120 (73-251)‡ 105 (68-198) 108 (68-222) 103 (67-194)
BNP (pmol/L) 1.5 (0.3-4.0) 1.3 (0.4-4.1) 1.3 (0.3- 3.7) 1.4 (0.4- 4.1) 1.3 (0.2- 4.7) 1.3 (0.4-4.0) 1.3 (0.3-4.2) 1.3 (0.4-4.0)
  1. BMI = Body Mass Index; NYHA = New York Heart Association functional class; HF = Heart Failure; IHD = Ischemic Heart Disease; AMI = Acute Myocardial Infarction; COPD = Chronic Obstructive Pulmonary Disease; TCI = Transient Cerebral Ischemia; ACE-I = Angiotensin Converting Enzyme-Inhibitor; AT-II = Angiotensin II receptor; WMI = Wall Motion Index; BNP = Brain Natriuretic Peptide; * p = 0.046; † p = 0.007; ‡ p = 0.025; ¤ p = 0.002; ¶ p = 0.022